Day One to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will engage in a pre-recorded discussion, available on November 22 at 10:00 a.m. ET. This talk highlights Day One's mission to develop targeted cancer therapies, particularly for pediatric patients. The company’s lead product candidate, DAY101, is currently in a pivotal clinical trial for low-grade glioma. Access the webcasts via the Company's website.

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that management will participate in a fireside chat discussion at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The pre-recorded webcast of the discussion will be available on Monday, November 22 at 10:00 a.m. ET.

To access the live and archived webcasts, please visit the News & Events section of the Company's website. A replay of the webcast will be available through the Company's website for 30 days thereafter.

About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Our name was inspired by the “The Day One Talk”¹ that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. We aim to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco. For more information, please visit www.dayonebio.com.

¹Jennifer W. Mack and Holcombe E. Grier; Journal of Clinical Oncology 2004 22:3, 563-566

Contacts:

Media:
1AB
Dan Budwick
dan@1abmedia.com

Investors:
LifeSci Advisors
Hans Vitzthum
hans@lifesciadvisors.com

FAQ

When is Day One Biopharmaceuticals participating in the Piper Sandler virtual conference?

Day One Biopharmaceuticals will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 at 10:00 a.m. ET.

What is the main focus of Day One Biopharmaceuticals?

Day One Biopharmaceuticals focuses on developing targeted therapies for patients of all ages with genomically defined cancers.

What is DAY101 and its significance for Day One Biopharmaceuticals?

DAY101 is the lead product candidate of Day One Biopharmaceuticals and is being evaluated in a pivotal Phase 2 clinical trial for pediatric patients with recurrent or progressive low-grade glioma.

How can I access the webcast of Day One Biopharmaceuticals' discussion?

The pre-recorded webcast will be available through the Company's website starting November 22 and can be accessed for 30 days after.